MM
Therapeutic Areas
Neumora Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Navacaprant | Major Depressive Disorder | Phase 3 |
| NMRA-511 | Agitation in Alzheimer's Disease | Phase 2 |
| NMRA-861 | Schizophrenia | Phase 1 |
| NMRA-898 | Schizophrenia | Preclinical |
| NMRA-215 | Obesity / Parkinson's Disease | Discovery |
| NMRA-GCASE | Parkinson's Disease | Discovery |
| NMRA-CK1δ | ALS / Parkinson's Disease | Discovery |
Leadership Team at Neumora Therapeutics
PL
Paul L. Berns
Chief Executive Officer
CS
Carol Suh
Chief Strategy Officer
NB
Nick Brandon
Chief Scientific Officer
LH
Lori Houle
Chief Technical Operations & Quality Officer
JP
Joshua Pinto
President
BA
Bill Aurora
Chief Operating & Development Officer
AS
Amy Sullivan
Chief Human Resources Officer
JD
Jason Duncan
Chief Legal & Administrative Officer
PG
Pablo Gersberg
Chief Information Officer